Avalo Therapeutics Downgraded by HC Wainwright and Guggenheim

Avalo Therapeutics, Inc. (AVTX) saw a decline in its share price after receiving downgrades from analysts at HC Wainwright and Guggenheim, who adjusted their ratings from Buy to Neutral. This change comes in light of recent market activity and competitive data releases within the biotechnology sector.